PubMed

アメリカにおける薬物耐性てんかんの治療に対する副次的治療としての迷走神経刺激の経済評価

PMID: 36691763 · 2023

C, h, r, i, s, t, o, p, h, e, r, , R, a, s, p, i, n, ;, , E, d, w, a, r, d, , F, a, u, g, h, t, ;, , J, e, a, n, n, e, , A, r, m, a, n, d, ;, , F, r, a, n, c, e, s, c, a, , B, a, r, i, o, n, ;, , V, i, c, k, i, , P, o, l, l, i, t, ;, , J, o, a, n, n, a, , M, u, r, p, h, y, ;, , V, a, n, e, s, s, a, , D, a, n, i, e, l, s, o, n

学術誌Journal of medical economics

年2023

PMID36691763

抄録

People with recurrent epileptic seizures are typically treated with anti-seizure medications (ASMs). Around a third of epilepsy patients fail to achieve an adequate response to ASMs and may be eligible to receive vagus nerve stimulation (VNS) therapy for their drug-resistant epilepsy (DRE) if they are unsuited to surgery. VNS received approval from the United States (US) Food and Drug Administration agency. However, there has to date been no comprehensive cost effectiveness evaluation of VNS wit

公式ソース

PubMedで見る →

データはPubMed / NCBIから取得しています。全文および最新情報は必ず公式記録をご確認ください。